Q-omics provides the consensus-scored ARHGAP20 profile across patient tissues and cancer cell-line models. ARHGAP20 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ARHGAP20 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, ARHGAP20 RNA expression shows 21,134 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, COAD, and BRCA as cancer lineages where ARHGAP20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGAP20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGAP20 survival associations across molecular data types. ARHGAP20 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGAP20 RNA expression–survival associations across cancer types. High ARHGAP20 expression shows unfavorable associations in KIRP, KICH, LGG and THCA, but favorable associations in KIRC and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for ARHGAP20 RNA expression.
This table summarizes ARHGAP20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ARHGAP20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGAP20 shows lower tumor expression in COAD, BLCA, HNSC, LUSC, UCEC and THCA. The COAD box plot shows higher ARHGAP20 RNA expression in normal versus tumor tissue (log2 FC = −1.146, t-test p < 0.001).
This table shows molecular features associated with ARHGAP20 in patient tissues and cancer cell lines. In patient samples, ARHGAP20 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, ARHGAP20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LUNG_NSCLC_LUAD.
